Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma.

Fisher R, Larkin J.

Cancer Manag Res. 2012;4:243-52. doi: 10.2147/CMAR.S25284. Epub 2012 Aug 8.

2.

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA.

Lancet Oncol. 2014 Aug;15(9):954-65. doi: 10.1016/S1470-2045(14)70301-8. Epub 2014 Jul 15. Erratum in: Lancet Oncol. 2014 Sep;15(10):417.

PMID:
25037139
3.

The role of BRAF V600 mutation in melanoma.

Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N.

J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85.

4.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A.

N Engl J Med. 2012 Feb 23;366(8):707-14. doi: 10.1056/NEJMoa1112302.

5.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.

Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.

PMID:
24582505
6.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A.

N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.

7.

Current and future roles of targeted therapy and immunotherapy in advanced melanoma.

Olszanski AJ.

J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. Review.

8.

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.

Ugurel S, Loquai C, Kähler K, Hassel J, Berking C, Zimmer L, Haubitz I, Satzger I, Müller-Brenne T, Mikhaimer NC, Becker JC, Kilian KJ, Schadendorf D, Heinzerling L, Kaatz M, Utikal J, Göppner D, Pföhler C, Pflugfelder A, Mössner R, Gutzmer R; Dermatologic Cooperative Oncology Group (DeCOG).

Ann Oncol. 2015 Mar;26(3):573-82. doi: 10.1093/annonc/mdu573. Epub 2014 Dec 18.

PMID:
25524477
9.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Ravnan MC, Matalka MS.

Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Review.

PMID:
22742884
10.

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.

Scholtens A, Geukes Foppen MH, Blank CU, van Thienen JV, van Tinteren H, Haanen JB.

Eur J Cancer. 2015 Mar;51(5):642-52. doi: 10.1016/j.ejca.2015.01.009. Epub 2015 Feb 15.

PMID:
25690538
11.

Drug safety evaluation of vemurafenib in the treatment of melanoma.

Tsai KY, Nowroozi S, Kim KB.

Expert Opin Drug Saf. 2013 Sep;12(5):767-75. doi: 10.1517/14740338.2013.813017. Epub 2013 Jun 26. Review.

PMID:
23800008
12.

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM.

JAMA Oncol. 2017 Nov 29. doi: 10.1001/jamaoncol.2017.5029. [Epub ahead of print]

PMID:
29188284
13.

Treatment of BRAF-mutated advanced cutaneous melanoma.

Trinh VA, You Y, Hwu WJ.

Chin Clin Oncol. 2014 Sep;3(3):28. doi: 10.3978/j.issn.2304-3865.2014.05.10.

14.

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.

J Clin Oncol. 2013 May 10;31(14):1767-74. doi: 10.1200/JCO.2012.44.7888. Epub 2013 Apr 8.

PMID:
23569304
15.

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.

Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD.

Eur J Cancer. 2014 Feb;50(3):611-21. doi: 10.1016/j.ejca.2013.11.002. Epub 2013 Nov 29.

PMID:
24295639
16.

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH, Giuliani R, Pignatti F.

Eur J Cancer. 2013 May;49(7):1654-61. doi: 10.1016/j.ejca.2013.01.015. Epub 2013 Mar 5.

PMID:
23481513
17.

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.

Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, Ottaviano V, Queirolo P.

Onco Targets Ther. 2015 Jan 16;8:157-68. doi: 10.2147/OTT.S39096. eCollection 2015. Review.

18.

Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.

Rutkowski P, Blank C.

Expert Opin Drug Saf. 2014 Sep;13(9):1249-58. doi: 10.1517/14740338.2014.939954. Epub 2014 Jul 11. Review.

PMID:
25014231
19.

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.

Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, Homicsko K, Michielin O.

Melanoma Res. 2014 Oct;24(5):496-500. doi: 10.1097/CMR.0000000000000055.

PMID:
25185693
20.

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.

Czirbesz K, Gorka E, Balatoni T, Pánczél G, Melegh K, Kovács P, Gézsi A, Liszkay G.

Pathol Oncol Res. 2017 Sep 29. doi: 10.1007/s12253-017-0324-1. [Epub ahead of print]

PMID:
28963614

Supplemental Content

Support Center